Page last updated: 2024-10-25

debrisoquin and Cancer of Lung

debrisoquin has been researched along with Cancer of Lung in 23 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Research Excerpts

ExcerptRelevanceReference
" Three examples of pharmacogenetic risk factors are discussed: the first two are p450 enzymes whose activity has been associated with susceptibility to lung cancer (debrisoquine hydroxylase, aryl hydrocarbon hydroxylase), and the last, N-acetyltransferase, a non-p450 enzyme, has been associated with bladder cancer susceptibility."3.68Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. ( Caporaso, N, 1991)
" Determination of debrisoquine oxidation phenotype was carried out in 119 healthy subjects, 135 patients with chronic bronchitis and 153 patients with lung cancer, all of Caucasian origin."3.68Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. ( Barre, J; Bechtel, P; Brochard, P; Dalphin, JC; de Cremoux, H; Depierre, A; Duche, JC; Joanne, C; Tillement, JP, 1991)
"Debrisoquine is an antihypertensive drug that is metabolized by cytochrome P4502D6."1.28The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. ( Caporaso, NE; Harris, CC; Hoover, R; Landi, MT; Shaw, GL; Shields, PG; Sugimura, H; Tucker, MA; Weston, A, 1992)
"Debrisoquine phenotyping has potential for identifying carcinogen-exposed workers at high risk of lung cancer."1.28Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. ( Ayesh, R; Caporaso, N; Dosemeci, M; Hayes, RB; Hetzel, M; Hoover, R; Idle, J, 1989)
"Accordingly, two groups of cancer patients were investigated with debrisoquine, namely Nigerians with hepatocellular and related tumours and white smokers with bronchial carcinoma in the United Kingdom."1.26Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis. ( Idle, JR; Ritchie, JC, 1982)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19905 (21.74)18.7374
1990's18 (78.26)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ritchie, JC1
Idle, JR1
Shaw, GL4
Falk, RT2
Deslauriers, J1
Nesbitt, JC1
McKneally, MF1
Frame, JN2
Feld, R1
Issaq, HJ3
Ruckdeschel, JC1
Hoover, RN4
Hirvonen, A1
Husgafvel-Pursiainen, K1
Anttila, S1
Karjalainen, A1
Pelkonen, O2
Vainio, H1
Smyth, JF1
Christensen, PM1
Gøtzsche, PC1
Brøsen, K1
Weiffenbach, B1
Moir, DT1
Caporaso, N5
Caporaso, NE4
Shields, PG1
Landi, MT1
Tucker, MA2
Hoover, R2
Sugimura, H2
Weston, A3
Harris, CC3
Horsmans, Y1
Desager, JP1
Harvengt, C1
Benítez, J1
Ladero, JM1
Jara, C1
Carrillo, JA1
Cobaleda, J1
Llerena, A1
Vargas, E1
Muñoz, JJ1
Duche, JC1
Joanne, C1
Barre, J1
de Cremoux, H1
Dalphin, JC1
Depierre, A1
Brochard, P1
Tillement, JP1
Bechtel, P1
Taghizadeh, K1
Tannenbaum, SR1
Skipper, PL1
Resau, JH3
Trump, BF2
Modali, RV1
Gonzalez, FJ1
Green-Gallo, LA1
Buivys, DM1
Fisher, KL1
Slawson, RG1
Elias, G1
Didolkar, MS1
Ivusich, WJ1
Speirs, CJ1
Murray, S1
Davies, DS2
Biola Mabadeje, AF1
Boobis, AR2
Law, MR2
Hayes, RB2
Pickle, LW2
Muschik, GM1
Green-Gallo, L1
Buivys, D1
Aisner, S1
Dosemeci, M1
Ayesh, R2
Hetzel, M2
Idle, J2
Hetzel, MR1
Idel, JR1
Bale, S1
Roots, I1
Drakoulis, N1
Ploch, M1
Heinemeyer, G1
Loddenkemper, R1
Minks, T1
Nitz, M1
Otte, F1
Koch, M1

Reviews

3 reviews available for debrisoquin and Cancer of Lung

ArticleYear
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    European journal of clinical pharmacology, 1997, Volume: 51, Issue:5

    Topics: Cytochrome P-450 CYP2D6; Debrisoquin; Disease Susceptibility; Genotype; Humans; Lung Neoplasms; Odds

1997
Carcinogen metabolism and individual susceptibility.
    Scandinavian journal of work, environment & health, 1992, Volume: 18 Suppl 1

    Topics: Acetylation; Animals; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carcinogens; Debrisoquin; Forecasti

1992
Genetic predisposition to lung cancer.
    British journal of cancer, 1990, Volume: 61, Issue:2

    Topics: Antigens, Neoplasm; Antipyrine; Aryl Hydrocarbon Hydroxylases; Chromosome Aberrations; Chromosome Di

1990

Other Studies

20 other studies available for debrisoquin and Cancer of Lung

ArticleYear
Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
    IARC scientific publications, 1982, Issue:39

    Topics: Animals; Biotransformation; Carcinoma, Bronchogenic; Debrisoquin; Humans; Isoquinolines; Lung Neopla

1982
Lung tumor resection does not affect debrisoquine metabolism.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1994, Volume: 3, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Debrisoquin; Female; Humans; Lung Neoplasms; M

1994
PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Pharmacogenetics, 1993, Volume: 3, Issue:1

    Topics: Aged; Alleles; Base Sequence; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin;

1993
Cancer genetics and cell and molecular biology. Is this the way forward?
    Chest, 1996, Volume: 109, Issue:5 Suppl

    Topics: Antihypertensive Agents; Antineoplastic Agents; Debrisoquin; Extracellular Matrix; Humans; Lung Neop

1996
Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
    Lung cancer (Amsterdam, Netherlands), 1997, Volume: 17, Issue:1

    Topics: Alleles; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP

1997
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
    Environmental health perspectives, 1992, Volume: 98

    Topics: Case-Control Studies; Debrisoquin; Genotype; Humans; Lung Neoplasms; Phenotype; Polymerase Chain Rea

1992
Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1991, Volume: 45, Issue:8

    Topics: Adult; Aged; Debrisoquin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxidation-Reduction; Ph

1991
Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
    Annali dell'Istituto superiore di sanita, 1991, Volume: 27, Issue:4

    Topics: Biotransformation; Carcinogens, Environmental; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytoch

1991
Polymorphic oxidation of debrisoquine in lung cancer patients.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:2

    Topics: Aged; Carcinoma, Bronchogenic; Debrisoquin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oxida

1991
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
    British journal of clinical pharmacology, 1991, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Bronchitis; Chronic Disease; Debrisoquin; Female; Humans; Lung Neopl

1991
Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls.
    Cancer research, 1991, Oct-01, Volume: 51, Issue:19

    Topics: Aminobiphenyl Compounds; Carcinogens; Case-Control Studies; Chromatography, Gas; Cotinine; Debrisoqu

1991
Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Carcinogenesis, 1990, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2D6; Cytochrome

1990
A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.
    Cancer, 1991, Jul-01, Volume: 68, Issue:1

    Topics: Blood Pressure; Case-Control Studies; Clinical Protocols; Debrisoquin; Humans; Lung Neoplasms; Middl

1991
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    British journal of clinical pharmacology, 1990, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Debrisoqui

1990
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    British journal of clinical pharmacology, 1990, Volume: 30, Issue:4

    Topics: Debrisoquin; Disease Susceptibility; Gas Chromatography-Mass Spectrometry; Humans; Lung Neoplasms; O

1990
Lung cancer and the debrisoquine metabolic phenotype.
    Journal of the National Cancer Institute, 1990, Aug-01, Volume: 82, Issue:15

    Topics: Adenocarcinoma; Case-Control Studies; Debrisoquin; Female; Humans; Isoquinolines; Lung Diseases, Obs

1990
Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
    Cancer research, 1989, Jul-01, Volume: 49, Issue:13

    Topics: Asbestos; Debrisoquin; Female; Humans; Isoquinolines; Lung Diseases, Obstructive; Lung Neoplasms; Ma

1989
Debrisoquine metabolism and genetic predisposition to lung cancer.
    British journal of cancer, 1989, Volume: 59, Issue:5

    Topics: Debrisoquin; Disease Susceptibility; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Age

1989
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Genetic epidemiology, 1989, Volume: 6, Issue:4

    Topics: Chromatography, Gas; Data Interpretation, Statistical; Debrisoquin; Gene Frequency; Genetic Predispo

1989
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Klinische Wochenschrift, 1988, Volume: 66 Suppl 11

    Topics: ABO Blood-Group System; Acetylation; Acetyltransferases; Arylamine N-Acetyltransferase; Caffeine; Ca

1988